This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response In Patients

NGX-1998 Phase 2 Study Data Presented at World Congress on Pain

Multiple Posters on Qutenza ® Presented by Partner Astellas

SAN MATEO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today presented data from its Phase 2 study on NGX-1998 at the 14th World Congress on Pain in Milan, Italy. NGX-1998 is the Company's next generation liquid formulation of prescription-strength capsaicin.

The presentation highlighted the Company's Phase 2 clinical trial, a multicenter, placebo-controlled, double-blind trial in postherpetic neuralgia (PHN). The results from the trial indicate that NGX-1998 may be a safe, efficacious and convenient treatment for patients with PHN and other types of neuropathic pain. NeurogesX plans to enable a Phase 3 clinical trial in neuropathic pain by the end of 2012.

Stephen J. Peroutka, MD, PhD, Chief Medical Officer of NeurogesX, said, "NGX-1998's liquid formulation allows for easier administration than our already approved capsaicin patch. Our Phase 2 results indicate that with a single, five minute treatment with NGX-1998, subjects experienced pain relief for as long as three months. The data from our Phase 2 study also confirm that NGX-1998 requires no topical anesthetic pre-treatment, making the therapy even more convenient for providers to administer."

Patients enrolled in the study had experienced pain for least 6 months following healing of a herpes zoster lesion, and had a Mean Numeric Pain Rating Scale (NPRS) score between 4 to 9, inclusive. Patients were randomized into one of three groups: NGX-1998 capsaicin 20% solution, NGX-1998 capsaicin 10% solution or placebo, according to an unequal allocation scheme of 2:2:1. Based on safety and tolerability results, it was determined that no topical anesthetic pre-treatment was required for treatment with NGX-1998. No patients discontinued the study due to adverse events, and the incidence of adverse events and serious adverse events in patients treated with NGX-1998 were similar to the placebo-treated group.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs